Regencell Bioscience Holdings Limited (RGC) Q4 2026 earnings summary

Executive summary

• Early-stage TCM developer focused on ADHD and ASD; no approved products or product revenue, with standardized formula still in development.

• FY2026 loss widened as operating costs rose; May 2026 offering strengthened liquidity, and management judged cash sufficient for at least 12 months.

Financial highlights

• Product revenue remained $0 in FY2026 and FY2025; operating expenses were $11.72M vs. $3.77M, up 211% YoY.

• Net loss was $11.70M vs. $3.58M in FY2025; loss per share was $2.37 vs. $0.72, on a cents-per-share basis.

• G&A expense rose to $10.42M from $2.81M, driven by $3.13M higher professional fees, $3.02M higher share-based compensation amortization and $1.47M higher payroll.

• R&D expense increased to $1.30M from $0.95M, mainly due to higher payroll; selling and marketing fell to $6.49K from $8.01K.

Outlook and guidance

• No product revenue expected until standardized TCM products are commercialized in Hong Kong; launch depends on further development, registration and manufacturer licensing.

• Next trial design and research partnerships are being explored; planned AI, blockchain and tokenization initiatives remain conceptual, with execution and regulatory feasibility uncertain.

• Cash at June 30, 2026 was assessed as sufficient for operating needs and obligations for at least the next 12 months; further financing may be pursued for reserves or expansion.